the company will receive proceeds of $8M 2/7/13 BrainStorm Cell Therapeutics Inc. (New York) Common stock purchase agreement 0.833S $0.25 BrainStorm raised $250,000 through an agreement with an individual private investor, selling 833,334 common shares at $0.30 per share with a 32-month warrant to purchase up to 0.833 shares of common stock at $0.50 per share 2/12/13 Celsion Corp. (Lawrenceville, N.J.) Registered direct offering 12.1S $15 Celsion received $15M in commitments from institutional

New York $10 Retrophin raised $10M by issuing 3.3M shares and warrants for 1.5M shares

The biotech IPOs that have priced in 2013 include antibody drug developer KaloBios Pharmaceuticals Inc., which priced a slightly upsized offering of 8.75 million shares at $8 apiece for gross proceeds of $70 million and Stemline Therapeutics Inc., of New York, which closed its IPO of 3.8 million shares, including the exercise in full of the overallotment option covering 497,647 shares, at a price of $10 per share

New York-based Pfizer Inc...Bristol-Myers Squibb Co., of New York and London-based AstraZeneca plc teamed up to buy Amylin Pharmaceuticals Inc., expanding their diabetes franchises

New York-based Royalty Pharma is offering the certainty of cash today vs...New York-based Leerink Swank analyst Marko Kozul recommended that shareholders accept the proposal as is

It's targeted, and if it's successful, we will be applying it in our manufacturing plants," Liam Tully, director of New York-based Pfizer's process development center in Ringaskiddy, Ireland, told BioWorld International

New York-based Pfizer Inc., meanwhile, is conducting a large Phase III development program in psoriasis with its JAK inhibitor, Xeljanz (tofacitinib), which already is approved in rheumatoid arthritis

Ablynx NV, of Ghent, Belgium, and Spirogen Ltd., of London, inked a research collaboration to evaluate the potential of a cancer drug conjugate combining Spirogen's cytotoxic drugs, pyrrolobenzodiazepines and associated linker technology, with Nanobodies generated using Ablynx's technology platform. Under the terms, Ablynx will provide access to Nanobodies against an undisclosed target, and Spirogen will provide access to its cytotoxic warheads and conjugation technologies. The collaboration

New York-based Pfizer Inc., meanwhile, is conducting a large Phase III development program in psoriasis with its JAK inhibitor, Xeljanz (tofacitinib), which already is approved in rheumatoid arthritis

New York-based Royalty Pharma is offering the certainty of cash today vs...New York-based Leerink Swank analyst Marko Kozul recommended that shareholders accept the proposal as is

New York law firm Bronstein, Gewirtz & Grossman LLC, for instance, said it was investigating potential claims on behalf of stockholders, focusing on whether the company and its execs violated federal securities laws. (See BioWorld Today, Dec. 18, 2006.) Omontys is Affymax's primary growth driver, and the firm, which recorded $100 million on its balance sheet as of Sept

New York-based Royalty Pharma is offering the certainty of cash today vs...New York-based Leerink Swank analyst Marko Kozul recommends that shareholders accept the proposal as is

The merger would result in the company becoming private and its American depositary shares would be delisted from the New York Stock Exchange

payments to Isis could total $200 million, including license fees and regulatory milestones per program, plus additional double-digit royalties 12/11/12 BrainStorm Cell Therapeutics Inc. (New York) Octane Biotech (Kingston, Ontario) ND Deal to jointly develop a bioreactor for production of its NurOwn stem cell therapy candidate The customized bioreactor will enable BrainStorm to optimize its NurOwn production process, and the project is supported by a grant from the Canada-Israel Industrial

Ltd. (New York) $2.5 The 2006 license agreement relating to Geron's telomerase activation technology for use in developing dietary food supplements, nutraceuticals and topically applied cosmetics has been terminated Geron agreed to assign to TA Sciences Inc., of New York, those patents previously licensed to Asia Biotech, including intellectual property relating to telomerase activation technology

Pfizer Inc., of New York, said top-line results from a Phase III study showed Lyrica (pregabalin) capsules CV were as effective as levetiracetam (Keppra, UCB SA) as adjunctive therapy for refractory partial onset seizures in adults with epilepsy

By Catherine Shaffer Staff Writer A partnership between Roche AG and Chiasma Inc., of New York, promises to take the pain out of therapy for acromegaly, the overproduction of growth hormone

Intra-Cellular Therapies Inc., of New York, said it completed a Phase I, single-rising-dose study of phosphodiesterase 1 inhibitor ITI-214

A partnership between Roche AG and Chiasma Inc., of New York, promises to take the pain out of therapy for acromegaly, the overproduction of growth hormone